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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYHistone H3K36 trimethylation (H3K36me3) is frequently lost in multiple cancer types, identifying it as an
important therapeutic target. Herewe identify a synthetic lethal interaction in which H3K36me3-deficient can-
cers are acutely sensitive to WEE1 inhibition. We show that RRM2, a ribonucleotide reductase subunit, is the
target of this synthetic lethal interaction. RRM2 is regulated by two pathways here: first, H3K36me3 facilitates
RRM2 expression through transcription initiation factor recruitment; second, WEE1 inhibition degrades
RRM2 through untimely CDK activation. Therefore, WEE1 inhibition in H3K36me3-deficient cells results in
RRM2 reduction, critical dNTP depletion, S-phase arrest, and apoptosis. Accordingly, this synthetic lethality
is suppressed by increasing RRM2 expression or inhibiting RRM2 degradation. Finally, we demonstrate that
WEE1 inhibitor AZD1775 regresses H3K36me3-deficient tumor xenografts.INTRODUCTION
Trimethylation of histone H3K36 (H3K36me3) is an epigenetic
mark usually associated with actively transcribed genes (Shilati-
fard, 2006), for which proposed functions includeDNA repair (Ay-
mard et al., 2014; Carvalho et al., 2014; Pfister et al., 2014), chro-
matin structure modulation during elongation (Carvalho et al.,
2013), and stem cell regulation (Zhang et al., 2014; Zhu et al.,
2014). Multiple mutations can cause loss of H3K36me3: loss of
the tumor suppressor SETD2 (the sole methyltransferase for
H3K36me3), overexpression of the oncogene KDM4A (which de-
methylates H3K36me3), or mutation of histone H3.3 (G34V/R or
K36M) (Lewis et al., 2013). Importantly, SETD2 under-expressionSignificance
Despite the high prevalence and poor prognosis associated wi
deficient cancers. Here we show these cancers can be targ
H3K36me3 and WEE1 in RRM2 regulation, nucleotide pool m
based on synthetic lethality, which provides a less toxic and m
cells. H3K36me3 loss can be used as a predictive biomarker, w
tient selection through immunohistochemistry. Finally, because
ical trials, we anticipate that these findings will be of immedia
Caandmutation areassociatedwithpoor prognosis inbreast cancer
(Al Sarakbi et al., 2009) and renal cancer (Hakimi et al., 2013), and
KDM4A overexpression is associated with poor patient outcome
in ovarian cancer (Black et al., 2013). SETD2 mutations and
KDM4A overexpression are together observed in more than
10% of cancers in kidney, large intestines, endometrium, and
ovary (Berry and Janknecht, 2013; Dalgliesh et al., 2010; Gerlin-
ger et al., 2012). Notably, in pediatric high-grade gliomas,
H3K36me3 is lost in 54% of cases (Fontebasso et al., 2013).
Despite its frequent loss and association with poor prognosis,
there is no therapy targeting H3K36me3-deficient cancers.
The WEE1 kinase inhibits the activities of cyclin-dependent ki-
nases CDK1 and CDK2 through tyrosine 15 phosphorylationth H3K36me3 loss, there is no therapy targeting H3K36me3-
eted by inhibition of WEE1. We identify distinct roles for
aintenance, and DNA replication. Our proposed therapy is
ore effective treatment because it specifically targets cancer
hich identifies multiple genetic mutations, and enables pa-
theWEE1 inhibitor, for whichwe describe a target, is in clin-
te clinical relevance.
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(Parker and Piwnica-Worms, 1992; Watanabe et al., 1995). Inhibi-
tion of WEE1 promotes unscheduled mitotic entry through CDK1
activation, leading to loss of genome integrity (Tominaga et al.,
2006). Recently, WEE1 inhibition has also been shown to induce
replication stress through CDK1/2-dependent aberrant firing of
replication origins and subsequent nucleotide shortage (Beck
etal., 2010,2012).AlthoughstudiesshowthatWEE1 inhibition sen-
sitizes p53-deficient cells to DNA damaging agents (Hirai et al.,
2009), others argue that the chemosensitization is independent of
p53 status (Van Linden et al., 2013). The WEE1 inhibitor AZD1775
(MK1775) is currently in multiple phase II clinical trials in combina-
tionwithDNA-damaging agents (http://www.clinicaltrials.gov), but
insights into the targeted use of this inhibitor are limited.
One way to target genetic defects in cancer is through syn-
thetic lethality. Synthetic lethality describes a genetic interaction
between two genes or two pathways, where loss of either one
alone has little effect on cell viability, but the simultaneous loss
of both results in cell death. Therefore, synthetic lethal interac-
tions can be exploited to selectively kill cancer cells that carry
mutations in one of the genes in the interaction by chemically in-
hibiting the second gene product (Chan andGiaccia, 2011). Here
we describe the targeting of H3K36me3-deficient cancers by ex-
ploiting a synthetic lethal interaction with WEE1 inhibition.
RESULTS
H3K36me3-Deficient Cancers Are Hypersensitive
to WEE1 Inhibition
From our unpublished results, we know that the loss of Set2
(a SETD2 ortholog) is synthetically lethal with the loss of Wee1
(a WEE1 ortholog) in Schizosaccharomyces pombe. We there-
fore tested whether SETD2-deficient human cells can be selec-
tively killed by inhibiting WEE1.
With four different approaches, we demonstrate that
H3K36me3-deficient cancer cells are hypersensitive toWEE1 in-
hibition. First, we found that two naturally occurring SETD2-defi-
cient cell lines (A498 and LB996) were hypersensitive to
AZD1775 (A498 half-maximal inhibitory concentration [IC50] =
87 nM, LB996 IC50 = 68 nM versus RCC4 IC50 = 673 nM,
U2OS IC50 = 712 nM) (p < 0.0001) (Figures 1A, 1B, and S1A).
A498, LB996, and RCC4 are renal cell carcinoma cell lines;
U2OS is an osteosarcoma cell line that is suitable for genetic
manipulation. A498 expresses a near full-length non-functional
SETD2 protein, whereas LB996 does not express the SETD2
protein. Expressing SETD2 cDNA in A498 cells restored
H3K36me3 levels and reduced sensitivity to AZD1775 (Figures
1A and 1C). Second, SETD2 knockdown with two independent
siRNAs sensitized cells to AZD1775 (Figures 1D and 1E). Third,
reduction of H3K36me3 was also achieved by overexpressing
the demethylase KDM4A and by expressing a mutant histone
H3.3K36M (Figure 1D). In both cases, U2OS cells were sensi-
tized to AZD1775 (KDM4A IC50 = 106 nM, K36M IC50 = 117 nM
versus control IC50 > 400 nM) (Figure 1F). Lastly, we generated
a SETD2-knockout cell line using CRISPR technology, where
the gRNA-guided DNA break led to a frameshift mutation and
a premature stop codon in both SETD2 alleles, resulting in loss
of the SETD2 protein (Figures 1G, S1B, and S1C). The SETD2-
knockout U2OS cells were hypersensitive to AZD1775
compared to the parental SETD2 wild-type U2OS cells (CRISPR558 Cancer Cell 28, 557–568, November 9, 2015 ª2015 The AuthorsIC50 = 151 nM versus parental IC50 = 615 nM) (p < 0.0001) (Fig-
ure 1H). This effect was not only due to growth inhibition, but
also cell killing, as evidenced by a 12-fold difference in clono-
genic survival (CRISPR IC50 = 10 nM versus parental IC50 =
128 nM) (Figure S1D), and an up to 8-fold increase in apoptosis
(Figure 1I). Moreover, siRNA knockdown of WEE1 selectively
killed CRISPR SETD2-knockout cells (Figure S1E), and
combining AZD1775 and WEE1 siRNA showed epistasis (Fig-
ure S1F), confirming that it is WEE1 inhibition that selectively kills
H3K36me3-deficient cells. We confirmed that WEE1 is inhibited
by AZD1775 by western blotting with pCDK1 Tyr15 and pan-
CDK substrates (Figure S1G), and that at the doses used,
AZD1775 was not inhibiting MYT1 (a kinase related to WEE1)
(Figure S1H). Together, results from the four different ap-
proaches above strongly suggest a synthetic lethal interaction
between H3K36me3 loss and WEE1 inhibition.
WEE1 Inhibition Abolishes DNA Replication
in SETD2-Deficient Cells
We next examined the mechanism underlying this selective
killing of SETD2-deficient cells, and observed a significant
disturbance in S-phase. In particular, WEE1 inhibitor AZD1775
forced 32% of the CRISPR SETD2-knockout cells to accumulate
as non-replicating S-phase cells (exhibiting a DNA content be-
tween 2N and 4N, but not incorporating the synthetic nucleoside
bromodeoxyuridine [BrdU]), whereas it had no effect on U2OS
parental cells (Figure 2A). The same effect was observed in
SETD2-deficient A498 cells: 40% of A498 cells accumulated in
non-replicating S-phase (Figure S2A). To study the progression
through S-phase, we pulse-labeled U2OS and A498 cells with
BrdU and measured the cell cycle progression of the labeled
cells every 2 hr. We found that while AZD1775 treatment had
no effect on U2OS cells, it arrested A498’s progression through
S-phase, leading to a 114-hr S-phase (calculated according to
published protocol [Begg et al., 1985]) (Figure S2B). In addition,
WEE1 inhibition significantly increased replication stress in
SETD2-depleted U2OS cells, as shown by a 3-fold increase in
pan-nuclear gH2AX staining compared to AZD1775-treated
control cells (Figure S2C). Consistently, in SETD2-knockout
U2OS cells, AZD1775 induced a 10-fold increase in both phos-
pho-CHK1 and phospho-RPA staining (indicators of replication
stress) compared to U2OS parental cells (Figure S2D). These
data suggest that the synthetic lethality resulted from inhibition
of DNA replication.
To understand the cause of S-phase arrest, we depicted the
progression of individual replication forks using the DNA fiber
assay. InU2OScells, fork velocitywasmildly reduced uponeither
SETD2 depletion or AZD1775 treatment (from an average of 0.6–
0.8 kb/min to 0.4–0.6 kb/min in both cases) (Figure 2B), suggest-
ing that both SETD2 and WEE1 are required for efficient DNA
replication. Strikingly, combining SETD2 depletion with
AZD1775 treatment abolished fork progression (average fork ve-
locity < 0.2 kb/min) (Figure 2B) and significantly increased fork
stalling, as demonstrated by a 3-fold increase in the percentage
of stalled forkscompared toAZD1775 treatment alone (measured
by fiber tracks that only contained the first label) (Figure S2E).
To study the molecular events at stalled replication forks, we
used iPOND (isolation of proteins on nascent DNA) (Sirbu
et al., 2012). In control cells (SETD2-proficient U2OS),
Figure 1. WEE1 Inhibition Selectively Kills H3K36me3-Deficient Cancer Cells
(A) Western blot analysis of SETD2 andH3K36me3 levels in A498, LB996, RCC4, and U2OS cells. A498 + SETD2 are A498 cells stably expressing aSETD2 cDNA.
(B) Viability curves of SETD2 wild-type (RCC4, U2OS) and SETD2-deficient (A498, LB996) cells after exposure to WEE1 inhibitor AZD1775 (5 days).
(C) Viability of A498 cells expressing either an empty vector (A498 + C) or SETD2 cDNA (A498 + SETD2) after exposure to AZD1775 (200 nM) (72 hr).
(D) Western blot analysis of SETD2, KDM4A, and H3K36me3 in U2OS cells transfected with either control siRNA (siNT) or SETD2 siRNAs (siSETD2#3,
siSETD2#5), and in U2OS cells stably expressing H3.3K36M or KDM4A.
(E) Viability curves of U2OS cells transfected with either control siRNA (siNT) or SETD2 siRNAs (siSETD2#3 and siSETD2#5) (48 hr) and exposed to AZD1775
(5 days).
(F) Viability curves of U2OS cells expressing either an empty vector, H3.3K36M, or KDM4A after exposure to AZD1775 (5 days).
(G) Western blot analysis of SETD2 and H3K36me3 levels in U2OS parental cells or U2OS cells with CRISPR knockout of SETD2.
(H) Viability curves of U2OS parental cells and U2OS SETD2 CRISPR knockout cells after exposure to AZD1775 (5 days).
(I) Percentage of apoptotic cells after exposure to AZD1775 (48 hr). For all graphs in Figure 1, data are presented asmean ± SEM, n = 3 independent experiments.
***p < 0.001, unpaired and two-tailed t test was used.
See also Figure S1.AZD1775 treatment resulted in transient RPA recruitment to
replication forks, which disappeared after 90 min following
thymidine chase (Figure 2C). No gH2AX was detected, suggest-
ing that AZD1775-induced replication stress was efficiently
resolved. In contrast, SETD2-deficient cells (A498) showed
RPA accumulation at forks even without AZD1775 treatment,Caindicating that SETD2 loss generated replication stress. Further-
more, upon AZD1775 treatment, gH2AX, RAD51 and RPA were
recruited to the replication forks, and remained after 90 min (Fig-
ure 2D). These experiments suggest that SETD2 depletion leads
to fork stalling, and upon additional WEE1 inhibition, stalled forks
collapse. Further investigation suggested that one of thencer Cell 28, 557–568, November 9, 2015 ª2015 The Authors 559
Figure 2. WEE1 Inhibitor AZD1775 Abolishes DNA Replication in SETD2-Deficient Cells
(A) BrdU FACS analysis of the cell cycle distribution of U2OS wild-type and U2OS SETD2 CRISPR knockout cells after exposure to DMSO (0.02%) or AZD1775
(200 nM) (48 hr).
(B) DNA fiber analysis of replication fork velocity in U2OS cells transfected with control siRNA (siNT) or SETD2 siRNAs (si#3 and si#5) (48 hr) prior to
treatment with DMSO or AZD1775 (200 nM) (48 hr). Representative images of the replication track after treatments; scale bar represents 5 mm (left). The
distribution of fork velocity was analyzed from >100 ongoing replication forks in each condition (right). Data are presented as mean ± SEM, n = 3 inde-
pendent experiments.
(legend continued on next page)
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mediators of the fork collapse is the endonuclease MUS81.
MUS81 is known to cleave stalled replication forks, resulting in
DNA double-stranded breaks (Hanada et al., 2007), which
become substrates for fork restart (Shimura et al., 2008) (Fig-
ure S2F). Indeed, MUS81 shRNA knockdown significantly
reduced DNA damage arising from combined depletion of
SETD2 and WEE1 in U2OS cells as measured by the comet
assay (Figures S2G–S2I).
The Synthetic Lethal Interaction Is Not Due to p53 Loss
or HR Deficiency
We next tested the possibility that p53 loss or homologous
recombination (HR) deficiency were the cause of synthetic
lethality with WEE1 inhibition. Previous publications showed
that p53-deficient cells are killed by WEE1 inhibitors through
mitotic catastrophe (Aarts et al., 2012). However, in our study,
p53-deficiency was not the cause of the SETD2-WEE1 synthetic
lethality. SETD2-deficient A498 and LB996 cells (which are sen-
sitive to WEE1) both have wild-type p53 (Warburton et al., 2005).
Moreover, SETD2 depletion did not affect p53 activity (Fig-
ure S2J). Therefore, WEE1 inhibition targets SETD2-deficient
cells via a mechanism that is distinct from that of p53-deficient
cells: SETD2-deficient cells exhibited S-phase arrest (Figures
2A, S2A, and S2B), but not premature mitosis (Figures S2K
and S2L), whereas p53-deficient cells exhibited premature
mitosis (Figures S2K and S2L), but not S-phase arrest (Figures
S2M and S2N).
We and others have shown that SETD2-dependent
H3K36me3 has a role in homologous recombination (HR) repair
of DNA double-stranded breaks through facilitating LEDGF and
CtIP binding to the chromatin (Aymard et al., 2014; Carvalho
et al., 2014; Kanu et al., 2015; Pfister et al., 2014). However,
HR deficiency is very unlikely to be the cause of sensitivity to
WEE1 because BRCA2-deficient cells were not hypersensitive
to WEE1 inhibition (Figure S2O). This is different from the recent
finding that BRCA2 knockdown sensitizes p53-negative cells to
WEE1 inhibition (Aarts et al., 2015): our cells are p53 positive,
and yet a much greater sensitization with SETD2 depletion was
observed. Second, if the role of SETD2 in HR was contributing
to the synthetic lethal interaction with WEE1 inhibition, then
depletion of the HR factors that are directly regulated by
SETD2 (e.g., LEDGF and CtIP) should also result in synthetic
lethality with WEE1 inhibition. However, when we depleted
LEDGF or CtIP by siRNA, U2OS cells were not hypersensitive
to the WEE1 inhibitor AZD1775, while the SETD2 siRNA control
was hypersensitive (Figure S2P). Third, if the role of SETD2 in
HR was contributing to this synthetic lethality, then SETD2
depletion in HR-defective cells should have no impact on
AZD1775 sensitivity (i.e., SETD2 and other HR factors should
be epistatic with regard to AZD1775 sensitivity). However,
SETD2 depletion further sensitized BRCA2-depleted cells to
AZD1775 (Figures S2Q and S2R), suggesting that SETD2 affects
a different pathway from HR in this synthetic lethal interaction.
Fourth, in S. pombe, the SETD2 ortholog Set2 is not required(C and D) U2OS (C) and A498 (D) cells were treated with DMSO or AZD1775 (200
thymidine chase (Thd Chase) (90min) and analyzed bywestern blots (left). Graphic
used to conjugate biotin to nascent DNA. No click acted as control with biotin a
See also Figure S2.
Cafor HR (Pai et al., 2014) yet it is synthetic lethal with loss of
Wee1. Lastly, HR-deficient cells are empirically known to arrest
in G2 phase upon DNA damage (Farmer et al., 2005), but
SETD2-knockout cells arrested in S-phase uponWEE1 inhibition
(Figure 2A). These five pieces of evidence argue that SETD20s
role in HR is not the main contributor to its synthetic lethal inter-
action with WEE1 inhibition.
H3K36me3 Facilitates RRM2 Transcription
We next investigated the cause of fork stalling and S-phase ar-
rest. It is known that loss of ribonucleotide reductase (RNR) leads
to fork stalling and S-phase arrest through deoxyribonucleoside
triphosphate (dNTP) depletion (Paulsen et al., 2009). Therefore,
we examined the levels of RNR subunits: RRM1, RRM2, and
P53R2. We found that RRM2 protein levels were reduced by
both AZD1775 treatment and SETD2 knockdown (siSETD2) in
U2OS, and combining them (siSETD2 + AZD1775) further
depleted RRM2, whereas RRM1 and P53R2 were unaffected
(Figure 3A). The same effect on RRM2 was also observed in
the isogenic wild-type andCRISPR SETD2-knockout U2OS cells
(Figure S3A). This reduction in RRM2 was not simply a cell cycle
effect, because combining SETD2 depletion andWEE1 inhibition
arrests cells in S-phase in which RRM2 levels are known to be
the highest (Chabes and Thelander, 2000). In addition, SETD2
depletion does not alter the cell cycle distribution (Figure S3B)
(Kanu et al., 2015; Pfister et al., 2014). This reduction was also
unlikely to be due to DNA damage because RRM2 levels in-
crease following DNA damage (D’Angiolella et al., 2012).
Synthetic lethality results from disruption of two independent
pathways, which together perform an essential function (in this
case DNA replication through RRM2 activity). To understand
how SETD2 depletion reduces RRM2 protein levels (the first
pathway), we performed qRT-PCR, and found that RRM2
mRNA levels were reduced by 60% by either SETD2 knockdown
or CRISPR SETD2-knockout (Figure 3B), suggesting that SETD2
affects the transcription of RRM2. This result was further
confirmed in naturally occurring SETD2-deficient cell lines
(A498 and LB996), where the RRM2 transcript and protein levels
were 60% lower than that in SETD2 wild-type cells (Figure 3C).
Reducing H3K36me3 independently of SETD2 mutation (e.g.,
expressing H3.3K36M) also reduced RRM2 levels (Figure S3C).
We next explored how SETD2 affects the transcription of
RRM2. Two genome-wide studies suggested a link between
H3K36me3 and RRM2 promoter activity: First, a chromatin
immunoprecipitation (ChIP) mass spectrometry study found
that 9 of 16 TBP-associated factors (TAFs) required for the initi-
ation of transcription by RNA polymerase II (Pol2) are enriched at
the histone mark H3K36me3 (Vermeulen et al., 2010). Second,
analysis of a ChIP-seq database (ENCODE) frommultiple cancer
cell lines showed enrichment for H3K36me3 at the RRM2 pro-
moter (Figure S3D). Consistent with the genome-wide studies,
we found, using ChIP-qPCR, that H3K36me3 was present at
the RRM2 promoter (Figures 3D and S3E), and recruited TAFs
to facilitate transcription initiation. Upon either SETD2nM, 24 hr), pulsed with EdU (10 min), and harvested either immediately or after
al representations of the iPOND data are shown on the right. Click reaction was
zide omitted.
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Figure 3. H3K36me3 Regulates RRM2
Expression
(A) Western blot analysis of RRM2, RRM1, and
P53R2 protein levels in U2OS cells transfected
with control (siNT) or SETD2 siRNA (siSETD2)
(48 hr) and exposed to either DMSO or AZD1775
(200 nM) (24 hr).
(B) qRT-PCR analysis of RRM2 mRNA levels in
siSETD2 U2OS cells (normalized to siNT) and in
CRISPR SETD2-knockout U2OS cells (normalized
to parental cells).
(C) qRT-PCR analysis of RRM2 mRNA levels in
SETD2-deficient (A498, LB996) and proficient
cells (U2OS, RCC4) (left). Western blot analysis of
RRM2 protein levels in these cells (right).
(D) ChIP analysis of the enrichment of H3K36me3,
TAF6, RNA-Pol2, and phospho-Pol2 (Ser5) at the
RRM2 promoter in U2OS cells transfected with
control siRNA (siNT) or SETD2 siRNA (siSETD2).
The qPCR data are presented as percentage of
input.
(E) Viability curves of U2OS cells transfected with
either control siRNA (siNT) or RRM2 siRNA
(siRRM2) (48 hr) and exposed to AZD1775 (5 days)
(left). Western blot analysis of RRM2 and RRM1
protein levels (right).
(F) Viability curves of U2OS cells treated with
DMSO, HU, or GM combined with indicated con-
centrations of AZD1775 (5 days). U2OS CRISPR
SETD2-knockout cells were used as a control. For
all graphs in Figure 3, data are presented as
mean ± SEM, n = 3 independent experiments.
***p < 0.001, **p < 0.01; *p < 0.05; n.s., not sig-
nificant. Unpaired and two-tailed t tests were used
for (D), and column statistics (one sample t test)
were used for (B) and (C).
See also Figure S3.knockdown or CRISPR SETD2 knockout, we observed signifi-
cantly reduced enrichment of H3K36me3, TAF6, Pol2, and
pSer5-Pol2 (serine 5 phosphorylation is associated with tran-
scription initiation) to the RRM2 promoter (Figures 3D and
S3E). The reduction in the promoter-bound Pol2 was also re-
flected in reduced occupancy of Pol2 throughout the gene
body of RRM2 in CRISPR SETD2-knockout cells (Figures S3F–
S3H). Consistent with this, pSer5-Pol2 (associated with 50 of
the gene) and pSer2-Pol2 (associated with 30 of the gene) were
also reduced at their corresponding positions in CRISPR
SETD2 knockout cells (Figures S3I and S3J). The reduction in
RRM2 transcription is not simply a global effect resulting from
H3K36me3 loss: previous RNA-seq studies found only a small
number of differentially expressed genes in SETD2-deficient
cells (Kanu et al., 2015). Together, these data suggest that
H3K36me3 modification regulates RRM2 transcription.
If the reduction in RRM2 (as a result of H3K36me3 loss) was
the cause of the sensitivity toward the WEE1 inhibitor
AZD1775, then RRM2 depletion or inhibition should resemble
H3K36me3 loss, and also exhibit synthetic lethality with
AZD1775. Indeed, depleting RRM2 by siRNA significantly sensi-562 Cancer Cell 28, 557–568, November 9, 2015 ª2015 The Authorstized SETD2 wild-type U2OS cells toward AZD1775 (siRRM2
IC50 = 157 nM versus siNT IC50 = 842 nM) (Figure 3E). Likewise,
inhibiting RRM2 by hydroxyurea (HU) or gemcitabine (GM) sensi-
tized the U2OS cells to AZD1775 (Figure 3F). Moreover, rescue
experiments show that transient expression of a RRM2 cDNA
reduced the sensitivity of SETD2-knockout cells toward
AZD1775 to a similar degree as a SETD2 cDNA (Figures S3K
and S3L). The data in this section together suggest that
H3K36me3 loss reduces RRM2 transcription, which sensitizes
cells to the WEE1 inhibitor AZD1775.
WEE1 Inhibition Promotes RRM2 Degradation through
CDK Activation
Next, we investigated how WEE1 inhibition reduces RRM2 pro-
tein levels (the second pathway). WEE1 restrains the activity of
CDK1/2 during S-phase (Beck et al., 2012), and CDK/SCFCyclin F
is known to promote the ubiquitin-mediated proteolysis of
RRM2 (D’Angiolella et al., 2012). Following CDK-mediated phos-
phorylation of RRM2 at Thr33, Cyclin F binds RRM2 at its CY
motif (residues 49–51 of RRM2), promoting RRM2 ubiquitylation
and degradation via SCFCyclin F. We found that WEE1 inhibition
leaves CDK1/2 activity unchecked, leading to untimely RRM2
degradation when dNTP is still needed.
First, we investigated the impact of WEE1 inhibition on RRM2
stability. Cycloheximide was used to block protein translation to
allowmeasurement of RRM2 half-life in the presence or absence
of the WEE1 inhibitor AZD1775. We found that AZD1775 treat-
ment reduced RRM2 half-life from over 8 hr to less than 2 hr in
both wild-type and CRISPR SETD2-knockout U2OS cells (Fig-
ure 4A). The reduction in half-life was accompanied by an in-
crease in RRM2 phosphorylation at Thr33 (Figure 4A), which
was shown to be mediated by CDK activity and signals it for
ubiquitination and proteolysis (D’Angiolella et al., 2012). This
AZD1775-induced increase in pRRM2 (T33) and reduction in
RRM2 levels can also be seen without cycloheximide (Fig-
ure S4A). As a control, RRM1, whose stability is not regulated
by CDKs, showed no change in half-life upon AZD1775 treat-
ment (Figure 4A). To confirm that RRM2 half-life was reduced
due to degradation, we used MG132 to block proteolysis, and
observed that RRM2 half-life was no longer reduced by
AZD1775, despite the increase in phosphorylation at T33 (Fig-
ure 4A). These data together suggest that WEE1 inhibition pro-
motes RRM2 degradation by increasing its phosphorylation at
T33. The impact of AZD1775 on RRM2 stability was the same
for both SETD2 wild-type and knockout cells (Figure 4A), the
only difference being that SETD2-knockout cells had less
RRM2 to start with due to reduced transcription, which lead to
critically low RRM2 levels in SETD2-knockout cells after
AZD1775 treatment (Figures 3A–3D).
Next, we tested whether CDK activation (due to WEE1 inhibi-
tion) degrades RRM2 and kills SETD2-deficient cells. We found
that in the presence of AZD1775, inhibiting CDK1 by RO3306
or inhibiting the NEDD8 activating enzyme with neddylation in-
hibitor MLN4924 (NAEi) (Soucy et al., 2009) (which blocks
cullin-mediated degradation of RRM2) both restored RRM2 pro-
tein levels and viability of A498 or SETD2-knockout U2OS cells
(Figures 4B and S4B). In addition to restoring cell viability,
RO3306 and MLN4924 also alleviated AZD1775-induced non-
replicating S-phase, replication stress, and apoptosis in
SETD2-deficient cells (Figures S4C–S4E). CDK2 inhibition by
CVT-313 (Brooks et al., 1997) also rescued the viability of A498
and SETD2-knockout cells (Figures 4B and S4B) and partially
restored RRM2 levels (Figure S4F).
To further support our hypothesis that WEE1 regulates RRM2
degradation in S-phase by inhibiting CDK, we reasoned that in-
hibiting other negative regulators of CDK such as CHK1 and
ATR, which also function in S-phase (Sørensen and Syljua˚sen,
2012), may have a similar impact on RRM2. Indeed, inhibition of
CHK1 and ATR reduced the inhibitory Y15 phosphorylation on
CDK1, leading to a significant reduction in RRM2 in SETD2-defi-
cient or depleted cells (FigureS4G).Consistentwith the reduction
in RRM2, inhibition of CHK1 and ATR selectively killed
H3K36me3-depleted cells (including CRISPR SETD2-knockout,
H3.3K36M expressing or KDM4A overexpressing cells) (Figures
S4H–S4K). As with WEE1 inhibition, treatment of SETD2-defi-
cient or depleted cells with CHK1 and ATR inhibitors resulted in
non-replicating S-phase (Figure S4L) and dNTP depletion (Fig-
ure S4M). In addition, the mechanism of rescue was the same:
CDK inhibition reduced the toxicity of CHK1 and ATR inhibitors
toward SETD2-deficient cells (Figure S4N). These data supportCaour hypothesis that WEE1 inhibition selectively kills H3K36me3-
deficient cells bypromotingCDK-dependentRRM2degradation.
Exogenous RRM2 Expression Rescues the Synthetic
Lethality
So far, we have shown that RRM2 levels are regulated by two
pathways in this context: H3K36me3 and CDK. In accordance
with RRM2 being the target of this synthetic lethal interaction,
we found that expressing exogenous RRM2 rescued the syn-
thetic lethality. We expressed amutant RRM2 (T33A) that cannot
be phosphorylated by CDK and degraded by SCFCyclin F (D’An-
giolella et al., 2012). Exogenous T33A expression increased
RRM2proteins to a level thatwas slightly lower than normal levels
(Figure 4C), and suppressed the sensitivity of SETD2-knockdown
or SETD2-knockout cells toward AZD1775 (Figures 4C andS3K).
In addition to T33A, the toxicity of the WEE1 inhibitor was also
suppressed by another RRM2 mutant: RxI/AxA, but not by wild-
type RRM2 (Figure S4O). The RxI/AxAmutation locates at the CY
motif of RRM2 (residue 49–51) and abolishes its interaction with
Cyclin F, thus preventing RRM2 degradation by proteolysis
(D’Angiolella et al., 2012). This suggests that WEE1 inhibition
promotes SCFCyclin F-mediated degradation of RRM2.
As expected, the reduction in RRM2 protein levels was re-
flected in reduced cellular dNTP levels. dATP levels were
reduced by 50% following either SETD2 depletion or AZD1775,
and by 70% when these treatments were combined (Figure 4D).
T33A expression, which restored RRM2 protein levels, also
restored dATP levels in AZD1775-treated SETD2-depleted cells
(Figure 4D). The other dNTP levels were also reduced by either
SETD2 depletion or AZD1775 treatment (Figure S4P), and the
reduction in dNTP levels was rescued by T33A expression (Fig-
ure S4Q). Together, these data support a model in which RRM2
is the target of the synthetic lethal interaction between
H3K36me3 loss and WEE1 inhibition.
WEE1 Inhibition Promotes Aberrant Origin Firing,
Enhancing the Toxicity of RRM2 Depletion
We have shown that RRM2 is transcriptionally regulated by
H3K36me3 and is degraded by WEE1 inhibition. Because
WEE1 inhibition also causes aberrant origin firing through CDK
activation, which (like RRM2 depletion) exhausts the dNTP
pool (Beck et al., 2012), we tested whether aberrant origin firing
worked together with RRM2 depletion to cause synthetic
lethality. Consistent with this, we found that reducing origin firing
by depleting CDC6 or CDT1 (replication licensing factors) (Beck
et al., 2012; Jones et al., 2013) suppressed the sensitivity of
SETD2-knockout cells toward AZD1775 (Figures 4E and S4R)
and reduced the non-replicating S-phase population by 50%
(Figure S4S). Furthermore, depleting CDT2 (part of the ubiquitin
ligase that degrades CDT1) (Jin et al., 2006) further sensitized
SETD2-knockout cells to RRM2 depletion (Figure 4F).
This proposed dual impact of WEE1 inhibition (RRM2 degra-
dation and aberrant origin firing) suggests that the traditional
inhibitors of RRM2 would be less efficient in killing H3K36me3-
deficient cells. Indeed, HU or GM (two inhibitors of ribonucleo-
tide reductase) sensitized SETD2-knockout cells, but neither
achieved a level of sensitivity comparable to the WEE1 inhibitor
AZD1775 (2-fold or less difference in IC50 for HU and GM versus
over 5-fold difference in IC50 for AZD1775 in the same assay)ncer Cell 28, 557–568, November 9, 2015 ª2015 The Authors 563
Figure 4. WEE1 Inhibition Promotes RRM2 Degradation and Aberrant Origin Firing
(A) U2OS and U2OS CRISPR SETD2-knockout cells were treated with cycloheximide (50 mg/ml) in the presence of DMSO, AZD1775 (400 nM), MG132 (10 mM) or
AZD1775 + MG132. Cells were collected at the indicated times, lysed, and immunoblotted as indicated.
(B) A498 cells were treated with AZD1775 (200 nM) combined with either DMSO, neddylation inhibitor MLN4924 (NAEi) (0.1 mM), CDK1 inhibitor RO3306 (CDK1i)
(10 mM) or CDK2 inhibitor (CVT-313) (3 mM).Western blot analysis of phospho-CDK1 (Y15) and RRM2 levels after indicated treatment (24 hr) (top). Viability of A498
cells after indicated treatment (72 hr) (bottom).
(C) U2OS cells expressing either an empty vector (Vector) or a degradation-resistant mutant RRM2 (T33A) were transfected with control siRNA (siNT) or SETD2
siRNA (siSETD2) (48 hr) prior to treatment with either DMSOor AZD1775 (200 nM).Western blot analysis of RRM2 levels after indicated treatment (24 hr) (top), and
viability of these cells after indicated treatment (96 hr) (bottom).
(legend continued on next page)
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Figure 5. WEE1 Inhibitor AZD1775 Re-
gresses SETD2-Deficient Tumors In Vivo
(A) Tumor volumes for each treatment group, with
arrows indicating the days when the inhibitors
were given. Data are presented as mean ± SEM,
n = 7 mice for A498 and U2OS, n = 5 mice for
LB996.
(B) Representative tumors in mice treated with
either AZD1775 or vehicle (day 13).
(C–F) Representative images of tumors generated
fromA498 cells (C and E) and quantification results
(D and F) of immunohistochemistry analysis of
pan-nuclear gH2AX (C and D) and cleaved-Cas-
pase-3 (CC3) (E and F) levels in tumors (day 13).
Scale bar represents 50 mm.Data are presented as
mean ± SEM, n = 3 tumors. ***p < 0.001; *p < 0.05;
unpaired and two-tailed t tests were used.
(G) Immunohistochemistry staining with anti-
H3K36me3 antibody to distinguish SETD2-defi-
cient from SETD2-proficient xenografts. Scale bar
represents 50 mm.
(H) Representative images of H3K36me3-negative
and H3K36me3-positive tumors identified by
immunohistochemistry staining of human renal
cancer patient tissue microarray. Scale bar rep-
resents 50 mm.
See also Figure S5.(Figures S4T and S4U). These data suggest that traditional inhib-
itors of RRM2 (HU and GM) cannot replace AZD1775 in targeting
H3K36me3-deficient cells.
WEE1 Inhibitor AZD1775 Regresses SETD2-Deficient
Tumors In Vivo
The selective and potent killing of SETD2-deficient cells by
AZD1775 suggested that AZD1775 could potentially be used to
treat H3K36me3-deficient cancers. To test the in vivo efficacy of(D) dATP levels in U2OS cells stably expressing either an empty vector (Vector) or a degradation-resistant m
(siNT) or SETD2 siRNA (siSETD2) (48 hr) prior to treatment with either DMSO or AZD1775 (200 nM) (24 hr). D
each cell line.
(E) Viability curves of U2OSCRISPR SETD2-knockout cells transfected with either control siRNA (siNT) or CDC
(5 days) (left). Western blot analysis of CDC6 protein levels (right).
(F) Viability of U2OS CRISPR SETD2-knockout cells transfected with control siRNA (siNT), RRM2 siRNA (s
siCDT2) (48 hr) (left). Western blot analysis of RRM2 and CDT2 protein levels (right). For all graphs in Figur
dependent experiments. ***p < 0.001; **p < 0.01; *p < 0.05; n.s., not significant. Unpaired and two-tailed t tests
(one sample t test) were used for (D).
See also Figure S4.
Cancer Cell 28, 557–568,AZD1775, we established tumor xeno-
grafts in nude mice. Upon AZD1775 treat-
ment, all seven tumors generated from
SETD2-deficient A498 cells regressed
from day 3 onward, resulting in a 5.8-fold
reduction in tumor size compared to
vehicle-treated control animals (tumor
size at day 12 = 50.2 ± 4.7 mm3 versus
291.2 ± 40.0 mm3, p < 0.0001) (Figures
5A and 5B). Consistent with the observa-
tion fromA498 cells, upon AZD1775 treat-
ment, all five tumors generated from
another SETD2-deficient cell line (LB996)regressed from day 3 onward, resulting in a 4.7-fold reduction in
tumor size compared to vehicle-treated control animals (tumor
size at day 12 = 66.5 ± 15.3 mm3 versus 313.3 ± 40.2 mm3, p <
0.0001) (Figure 5A). In contrast, AZD1775 treatment of tumors
generated fromSETD2-proficientU2OScells did not haveany sig-
nificant effect on tumor growth (tumor size at day 12 = 257.5 ±
19.3mm3 versus 292.5 ± 34.3mm3, p = 0.37) (Figures 5A and 5B).
Consistent with the in vitro data, AZD1775-treated SETD2-
deficient tumors showed significantly greater levels of replicationutant RRM2 (T33A), transfected with control siRNA
ata are normalized to the control (siNT + DMSO) of
6 siRNA (siCDC6) (48 hr) and exposed to AZD1775
iRRM2), CDT2 siRNA (siCDT2), or both (siRRM2 +
e 4, data are presented as mean ± SEM, n = 3 in-
were used for (B), (C), and (F), and column statistics
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Figure 6. SchematicOverview of the Synthetic Lethal Interaction be-
tween H3K36me3 Loss and WEE1 Inhibition
RRM2 is regulated by two pathways. In the first, SETD2 catalyzes histone
H3K36me3, which promotes RRM2 expression. In the second, WEE1 nega-
tively regulates CDK activity and upon WEE1 inhibition, hyperactive CDK
promotes RRM2 degradation and aberrant origin firing. Therefore, WEE1 in-
hibition in H3K36me3-deficient cells leads to critically reduced dNTP pool
levels, resulting in replication stress and cell death.stress (measured by gH2AX pan-nuclear staining) (Figures 5C
and 5D), accompanied by increased apoptosis (measured by
cleaved caspase-3) compared with vehicle-treated control (Fig-
ures 5E and 5F). No difference in body weight was observed be-
tween AZD1775-treated mice and the vehicle-treated control
(Figure S5), suggesting that AZD1775 was well tolerated.
Finally, to identify patients who could benefit from this treat-
ment, we sought a single biomarker to identify all the genetic
mutations that lead to loss of H3K36me3. Using a monoclonal
antibody against H3K36me3, we were able to distinguish
SETD2-deficient from SETD2-proficient tumor xenografts by
immunohistochemistry (IHC) (Figure 5G). Importantly, the same
IHC method worked on fixed patient tissue microarrays
(TMAs), thus enabling us to identify cancer patients with
H3K36me3-negative tumors. Using this method, we analyzed
renal cancer TMAs and found that 22 out of 122 (18%) cancers
showed complete loss of H3K36me3 (while stromal tissue
showed normal staining for H3K36me3) (Figure 5H). This high
prevalence of H3K36me3 loss further supports themedical inter-
vention of treating H3K36me3-deficient cancers with the WEE1
inhibitor AZD1775.
DISCUSSION
Despite the frequent loss of histone H3K36me3 in multiple can-
cer types and its association with poor patient outcome, there is
no therapy targeting H3K36me3-deficient cancers. Although
WEE1 inhibitors are currently in clinical trials, insights into deter-
minants of sensitivity to WEE1 inhibitors are limited. Here, we
identified a synthetic lethal interaction between loss of
H3K36me3 and inhibition of WEE1. We established RRM2, a
subunit of ribonucleotide reductase, to be the target of this syn-
thetic lethal interaction, and showed it to be regulated by two
pathways in this context. Disrupting the first pathway through
H3K36me3 depletion reduces RRM2 expression and dNTP pro-
duction. Disrupting the second pathway throughWEE1 inhibition
leads to aberrant CDK activity in S-phase, resulting in untimely
RRM2 degradation, aberrant origin firing, and reduced dNTP
pool levels. Simultaneous disruption of both pathways leads to566 Cancer Cell 28, 557–568, November 9, 2015 ª2015 The Authorscritically low RRM2 levels, dNTP pool depletion, inhibition of
DNA replication, and cell death (Figure 6).
We have identified a role for SETD2-dependent H3K36me3 in
facilitating RRM2-dependent nucleotide synthesis and efficient
DNA replication. In all H3K36me3-deficient cell lines tested,
RRM2 levels were consistently reduced. This is not simply a
cell cycle effect because H3K36me3-depletion had no effect
on the cell cycle (Aymard et al., 2014; Kanu et al., 2015; Pfister
et al., 2014). Nor is this a DNA damage effect because RRM2
levels increase after DNA damage (D’Angiolella et al., 2012).
Furthermore, this is not a result of global H3K36me3 loss
because SETD2 depletion only changes the expression of a
small subset of genes (Kanu et al., 2015).
The role of H3K36me3 in transcription initiation of RRM2 is
perhaps unexpected, because H3K36me3 has previously been
shown to be present mainly at the coding region of genes. How-
ever, our ChIP experiments and analysis of the ENCODE as well
as ChIP mass-spectrometry data suggest a role in transcription:
H3K36me3 is present at the promoter of RRM2 and recruits
transcription initiation factors (e.g., TAFs). This finding is in
accordance with the recent report of a role for murine SETD2
in transcriptional initiation of genes that are involved in endothe-
lial differentiation (Zhang et al., 2014). In the absence of
H3K36me3, RRM2 and dNTP levels are reduced, resulting in
low levels of replication stress, but without obvious cell cycle ef-
fects. However, we anticipate that the replication stress gener-
ated by H3K36me3 loss promotes genome instability, an
enabling characteristic of cancer. This finding, in conjunction
with additional recently defined roles for H3K36me3 in maintain-
ing genome stability (Kanu et al., 2015; Pfister et al., 2014; Sato
et al., 2013; Zhu et al., 2014) further suggests how loss of this his-
tone mark can promote tumorigenesis.
Our findings also suggest that the RRM2 inhibitors HU andGM
cannot replace AZD1775 in targeting H3K36me3-deficient cells.
This is because a second effect of WEE1 inhibition (aberrant
origin firing) works together with RRM2 degradation to kill
H3K36me3-deficient cells. We showed that depleting RRM2
without increasing origin firing (e.g., by siRRM2, HU or GM), or
increasing origin firing without depleting RRM2 (e.g., by siCDT2
alone), is less efficient in killing H3K36me3-deficient cells than
combining aberrant origin firingwithRRM2depletion. These find-
ings advance our current understanding of WEE1 inhibition,
showing that it induces replication stress through RRM2 deple-
tion as well as aberrant origin firing (Beck et al., 2012). The syn-
ergy betweenAZD1775 andHU/GM further supports our hypoth-
esis that dNTP levels are the main mechanism underlying the
synthetic lethal interaction. However, our data indicate that
AZD1775+HU/GM is likely tobea lethal combination in theclinic,
being toxic for all cells. In contrast, AZD1775 treatment selec-
tively affects cancer cells by targeting H3K36me3-deficiency.
In summary, we define a synthetic lethality between
H3K36me3 loss and WEE1 inhibition, and its underlying mecha-
nisms, by a variety of experimental approaches in many cell
lines. We further demonstrate that H3K36me3-deficient cancers
can be targeted in vivo by exploiting this synthetic lethal relation-
ship. The sensitivity to the WEE1 inhibitor results through DNA
replication stress because of RRM2 depletion, suggesting that
other cancers exhibiting such replication stress may be targeted
similarly. Because the WEE1 inhibitor, AZD1775, is already in
clinical trials, and because we have identified a testable predic-
tive biomarker for loss of H3K36me3, we expect our findings to
be of immediate clinical relevance.
EXPERIMENTAL PROCEDURES
Generation of CRISPR SETD2 Knockout Cells
The CRISPR plasmid was purchased from Horizon Discovery Group, and the
plasmid (pD1301) contains the chimeric gRNA scaffold, Cas9 and DasherGFP.
The target sequence of the gRNA is ACTCTGATCGTCGCTACCAT (first exon
ofSETD2). The plasmidwas transfected into U2OS cells using Fugene6 (Prom-
ega) and single-cell colonies of GFP-positive cells were selected and validated
by western blotting and genomic PCR.
iPOND
A total of 3 3 107 cells were treated with the AZD1775 or DMSO (24 hr) and
pulsed with 10 mM EdU (10 min), after which they were either crosslinked
(1% formaldehyde in PBS), or washed and released into fresh medium con-
taining 10 mM thymidine and AZD1775/DMSO for additional 90 min before
crosslinking. The click reaction was performed according to the published pro-
tocol (Sirbu et al., 2012). Samples were boiled (30 min) to de-crosslink proteins
before western blotting.
Measurement of dNTP Pools
Nucleotides were extracted by incubating cells in 60% methanol (1 hr) at
20C. Samples were boiled (3 min) and centrifuged at 13,000 3 g (10 min)
to remove cellular debris. The supernatant was dried and dissolved in sterile
water. Determination of the dNTP pool size was based on DNA polymerase-
catalyzed incorporation of radioactive dNTP into synthetic oligonucleotide
templates as described (Sherman and Fyfe, 1989).
Xenograft Studies
Mice were given food and water ad libitum, and all animal procedures were
carried out under a project license issued by the home office (London, United
Kingdom) following ethical review by the University of Oxford Committee on
Animal Care, and performed according to United Kingdom Coordinating Com-
mittee on Cancer Research guidelines. BALB/C nudemice (female, 6–8 weeks
old) were injected subcutaneously with A498, LB996, or U2OS tumor cells (53
106 cells per mouse in 50% v/v Matrigel, 14 mice for A498 and U2OS, 10 for
LB996). When the mean tumor size reached 110 mm3, mice were divided
into two equal groups. Group 1 received vehicle alone (0.5% w/v methylcellu-
lose, 0.1 ml/10 g body weight, twice daily by oral gavage) for 12 days. Group 2
received AZD1775 (60 mg/kg in 0.5% w/v methylcellulose, 0.1 ml/10 g body
weight, twice daily by oral gavage) for 12 days. Tumor size was determined
by caliper measurements and calculated as (width 3 length 3 height) /2. All
mice in the control group were killed on day 13, 24 hr after the last dose of
vehicle. Three mice in the treatment group were killed on day 13, 24 hr after
the last dose of AZD1775, and tumor re-growth in any remaining mice was fol-
lowed until day 33, when all remaining mice were killed.
Immunohistochemistry on Tissue Microarray
Use of human tissues in research was approved by National Research Ethics
Service Committee Oxfordshire REC C (study 07/H0606/120). Nephrectomies
were collected between 1995 and 2004, with informed consent from all
subjects to use of tissue in ethically approved research. Formalin-fixed
paraffin-embedded tumor cores were used to construct renal cancer tissue
microarrays, and 4 mm sections were stained on Bondmax Autostainer (Leica).
Briefly, following heat-induced epitope retrieval (20 min, pH 9) sections were
stained with an antibody against H3K36me3 (Mab-183-050, Diagenode) at
1:1,000 dilution for 1 hr. Antibody binding was identified using a Polymer
Detection System (Leica), followed by 3,30-diaminobenzidine staining.
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